New hope for kids with tough cancer: drug combo trial launches
NCT ID NCT07537400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug naxitamab to standard chemotherapy is safe and effective for children and young adults newly diagnosed with high-risk neuroblastoma, an aggressive nerve cell cancer. Ten participants aged 1 to 21 will receive the combination and be monitored for side effects and tumor response. The goal is to improve outcomes without increasing harm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shaare Zedek Medical Center
Jerusalem, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy boosts chemo against tough childhood cancer
- New antibody combo shows promise in tough childhood cancer
- Experimental cancer therapy targets tough tumors with radioactive precision
- New vaccine aims to train immune system to attack childhood cancer
- New drug combo shows promise against childhood cancer
- Promising combo targets Hard-to-Treat childhood cancers